Altamira Therapeutics Ltd. Current Accrued Expenses And Other Current Liabilities
Altamira Therapeutics Ltd. (CYTOF) had Current Accrued Expenses And Other Current Liabilities of CHF 348.84 thousand as of 2023-12-31, per its 20-F/A filed 2024-04-22.
Discontinued › Notes
ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities · last filed 2024-04-22
- 2023-12-31: Current Accrued Expenses And Other Current Liabilities 348.84K CHF.
- 2022-12-31: Current Accrued Expenses And Other Current Liabilities 1.98M CHF.
- 2021-12-31: Current Accrued Expenses And Other Current Liabilities 1.05M CHF.
- 2020-12-31: Current Accrued Expenses And Other Current Liabilities 1.43M CHF.
| Period end | Current Accrued Expenses And Other Current Liabilities |
|---|---|
| 2023-12-31 | 348.84K CHF 20-F/A · filed 2024-04-22 |
| 2022-12-31 | 1.98M CHF 20-F/A · filed 2024-04-22 |
| 2021-12-31 | 1.05M CHF 20-F · filed 2023-05-16 |
| 2020-12-31 | 1.43M CHF 20-F · filed 2022-04-12 |
| 2020-06-30 | 1.17M CHF 6-K/A · filed 2020-09-17 |
| 2019-12-31 | 1.34M CHF 20-F · filed 2021-03-31 |
| 2019-06-30 | 945.57K CHF 6-K · filed 2019-08-15 |
| 2018-12-31 | 1.29M CHF 20-F · filed 2020-04-16 |